Greater Cannabis Company Inc (GCAN)

[No-Quarter]

Well let me try to answer your questions.

There is no dilution, so the possible sources of shares being sold these days is limited to current shareholders. Wayne has sold some per his filings. Some are selling for yearend tax reasons. Could be one or more of the current lenders is selling for their own reasons. I'm not sure it matters as long as there is no dilution. Life happen, and some have to sell and move on for their own reasons.

We know GCAN and Symtomax have partnered –

http://www.globenewswire.com/news-release/2019/05/07/1818383/0/en/GREATER-CANNABIS-COMPANY-PARTNERS-WITH-SYMTOMAX-TO-EXPAND-ACROSS-EUROPE-THE-MIDDLE-EAST-AND-AFRICA.html?ev=1

We know GCAN and Symtomax are working together. So much so that GCAN was able to put their own person on the Symtomax board of directors.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152010251

We know Symtomax is floating a bond offering to finance their start-up grow facility in Portugal –

https://bondreview.co.uk/2019/10/30/we-review-symtomaxs-bonds-paying-30-over-two-years-for-investing-in-cannabis/

Here is a copy of the presentation materials used with their ‘Road Show’ as they traveled to meet with hedge fund and trust fund managers to promote their bond issue –

https://584b0793-b92b-45b5-9ba6-9836eefa77ad.filesusr.com/ugd/0d46e8_2ebc92961fa943e69077c35b8a3a9eb7.pdf

I like this page the best –

https://investorshub.advfn.com/uimage/uploads/2019/12/17/su[ssSlide6.PNG

We know Symtomax has purchased land –

https://investorshub.advfn.com/uimage/uploads/2019/12/17/axxchSlide5.PNG

We know Symtomax is hiring people –

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152010715

Here is one key hire in particular –

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152013306

We know GCAN restructured its debt a few months back to coincide with their business plan with Symtomax. IF GCAN obtains revenues in Q4 2019, or early Q1 2020, they will be able to pay off the EMET notes in cash, not shares, avoiding dilution –

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=152700396

This restructured debt schedule fits with the information contained in the Road Show presentation material referenced above, again page 6 –

“The Oral Tab is our retail product which is scheduled to launch in the first Qtr 2020, initially with external CBD and later substituted with our own product from our own plants.”

We know Symtomax has a plan to grow into a €37($41) million company in 2020. €77($85) million in 2021. €120($133) million in 2022. (€1.00 = $1.11)

https://investorshub.advfn.com/uimage/uploads/2019/12/17/vkwrlSlide8.PNG

We know GCAN is a fully reporting US based company. Symtomax is dependent on the GCAN patent for its Oraltabs. Some here are speculating this is a match ripe for a merger/acquisition.

…and for this last one I have no link to offer as proof, so you will have to trust me. I have knowledge samples of Symtomax produced Oraltabs, utilizing the GCAN technology, have been placed in the hands of members of this board for evaluation. Oraltabs are real. Production of Oraltabs has begun.

So what does all this mean? It means we sit back and watch and wait for 12 FEB 2020 when the EMET note is due, for the following week on 20 FEB 2020 when the Q4 2019 GCAN financial report filings are due. In my opinion, PR’s will be released leading up to these two dates that will make us all smile. News could become available on any day leading up to February too. Stay tuned.